Biography:

Aysehan Akinci  has completed  her  medical training  at the age of 25 years from Ankara  University Medical Faculty and Pediatric Endocrinology  training  from Hacettepe University Medical Faculty, Ankara. She is the director of Pediatric Endocrinology Department of her  medical Faculty.  She has published more than 45 papers in reputed journals. 
 

 

Abstract:

Fibroblast growth factor (FGF-23) is a hormonal regulator of circulating phosphate and vitamin D levels, and it may also act as a 'hormone-like' factor involved in the glucose and fat metabolism. Some studies have showen that FGF-23 has a potential role in the development of insulin resistance and vascular dysfunction and adverse thickening of the vascular wall, however ,it remains controversial. It was to investigate the possible correlations between serum FGF-23 levels and body compositions, insulin resistance and carotid intima media thickness (cIMT) in obese adolescents. The study included 46 obese adolescents (22 boys and 24 girls) and 46 non-obese healthy adolescents (18 girls and 28 boys). The exclusion criteria were presence of disorders of calcium phosphor metabolism or any chronic diseases. HOMA-IR values were calculated by using fasting insulin and blood glucose values in all patients and controls. Plasma FGF-23 level was measured using ELISA, cIMT was evaluated ultrasonographically. HOMA-IR , fasting insulin levels were significantly higher in obese group than controls, but FGF-23 and klotho levels were significantly lower in obese group (FGF-23: 310 ± 97 pg/ml, Klotho: 33.45 ± 10.9 pg/ml) when compared with controls ( FGF-23: 515.71 ± 142 pg/ml, Klotho: 56.17 ± 22 pg/ml). In this group, FGF-23 and Klotho were negatively correlated fasting insulin and HOMA-IR. cIMT values were incresead in obese group (0.56 mm) than those of controls (0.41 mm) and positively correlated with BMI, fasting insulin and HOMA-IR level, but not FGF-23 levels. These findings suggest that incresed insulin level may cause of lower FGF-23 and klotho levels in obese patients. Increased cMIT is more likely related to insulin resistance, but not FGF-23 in obese patients.